Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18723300 | 0.86 | — | — | |
| SCHEMBL20980228 | 0.80 | TP53 (0.36) | LMNA | |
| SCHEMBL18426964 | 0.77 | ALOX15 (0.34) | TSHRALDH1A1USP2 | |
| SCHEMBL3121279 | 0.71 | TSHR (0.44) | TSHRALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL3117794 | 0.71 | TSHR (0.44) | TSHRALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL24500940 | 0.69 | TSHR (0.35) | TSHRALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL2139099 | 0.67 | MAPT (0.50) | TSHRALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL10027888 | 0.67 | MAPT (0.50) | TSHRALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL9540135 | 0.67 | MAPT (0.50) | TSHRALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL10027891 | 0.67 | MAPT (0.50) | TSHRALDH1A1MAPTUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308231-A9 | SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-10-01 | — | — | US | disclosed |
| US-20190300576-A1 | SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308231-A9 | SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES | TP53, MDM2, MDM4 | TSHR 4784/4885ALDH1A1 4342/4885MAPT 768/4885 |
| US-20190300576-A1 | SOLUTION-PHASE AFFINITY SELECTION OF INHIBITORS FROM COMBINATORIAL PEPTIDE LIBRARIES | TP53, MDM2, MDM4 | TSHR 4784/4885ALDH1A1 4342/4885MAPT 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.